Skip to content

Anxiety, Stress and Pain & Myocardial Infarction

The Impact of Anxiety, Stress and Pain in the Early Phase of Myocardial Infarction on the Development of Anxiety Symptoms and Posttraumatic Stress Disorder in the Long Term Outcome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04130269
Enrollment
100
Registered
2019-10-17
Start date
2020-04-07
Completion date
2027-12-07
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Brief summary

People often experience the acute phase of a myocardial infarction as a stressful and traumatic event that seems lifethreatening. Such anxiety, pain and stress can lead to the development of posttraumatic stress disorder in the long run. Previous studies suggest that there might be a relevant percentage of people developing Posttraumatic Stress Disorder (PTSD) after a myocardial infarction. Posttraumatic stress disorder is a risk factor for the development of coronary heart disease. The goal of this study is to detect the percentage of people that develop symptoms of anxiety, stress, and PTSD after an acute myocardial infarction.

Detailed description

People often experience the acute phase of a myocardial infarction as a stressful and traumatic event that seems lifethreatening. Such anxiety, pain and stress can lead to the development of posttraumatic stress disorder in the long run. Previous studies suggest that there might be a relevant percentage of people developing PTSD after a myocardial infarction. Posttraumatic stress disorder is a risk factor for the development of coronary heart disease. The goal of this study is to detect the percentage of people that develop symptoms of anxiety, stress and PTSD after an acute myocardial infarction. Patients will be examined during three times - in the acute myocardial infarction period (Day 1-3), before dismissal (Day 5-14) and after 6 months for a follow-up. During all times they will be given questionnaires asking about their levels of stress, anxiety and general well-being as well as tests checking their cognitive abilities (thus to find out if they decrease over time). Moreover, blood samples checking cortisol levels as well as metanephrine levels will be taken in order to objectify the levels of stress that are stated by the patients. Furthermore, clinical evaluations, laboratory runs (troponin), ECGs and echocardiographies will be done at all three points in time. The goal is to detect the biopsychosocial relations and to develop better prevention.

Interventions

OTHERNo intervention

Questionnaires, lab-run

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* willingness to participate in the study * men and women 19-90 * after myocardial infarctions * no psychiatric disease before myocardial infarction * no other severe disease influencing the immune system

Exclusion criteria

* non fulfilment of inclusion criteria * non-compliant patients (dementia, delirium) * steroid-therapy

Design outcomes

Primary

MeasureTime frameDescription
PTSD6 monthsNumber of patients who develop PTSD

Countries

Austria

Contacts

Primary ContactAndreas Baranyi, MD
an.baranyi@medunigraz.at004331638513612
Backup ContactHans-Bernd Rothenhäusler, MD
004331638513612

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026